STAT+: U.K. decision blocks a pair of Alzheimer\u2019s drugs from access through its national health service
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
LONDON \u2014 A U.K. health agency reiterated on Thursday that the limited benefits of a pair of new Alzheimer\u2019s drugs do not justify their high prices, meaning the medicines won\u2019t be made available through the National Health Service.<\/p>\n
The decision by the U.K.\u2019s cost-effectiveness watchdog reflects how health authorities in different parts of the world have taken different approaches with the drugs, which are the first to have shown they can slow the progression of the disease but have stoked debate about just how meaningful that progress is for patients and how to weigh their accompanying risks and costs.<\/p>\n
The drugs \u2014 Eli Lilly\u2019s Kisunla (also known as donanemab) and Biogen and Eisai\u2019s Leqembi (lecanemab) \u2014 won approval from U.K. regulators last year, with the Medicines and Healthcare products Regulatory Agency finding the benefits of the drugs outweighed the risks for certain patients.<\/p>\n
Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n